$VCYT News

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer - Slideshow

Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

Needham Maintains Buy on Veracyte, Raises Price Target to $57

Veracyte Commercially Rolls Out Prosigna Breast Risk Of Recurrence Test Across U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte To Present Results From Independent OPTIMA Trial, Led By University College London, At ASCO Annual Meeting

Needham Reiterates Buy on Veracyte, Maintains $48 Price Target

Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

Veracyte to Participate in Upcoming Investor Conferences

Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are

Veracyte, Inc. 2026 Q1 - Results - Earnings Call Presentation

Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors